<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part6">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>6</PartID>
        <PartNumber>Part V</PartNumber>
        <PartSequenceNumber>6</PartSequenceNumber>
        <PartTitle>Immunotherapy</PartTitle>
        <PartChapterCount>4</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap27" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>27</ChapterID>
          <ChapterNumber>Chapter 27</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_27</ChapterDOI>
          <ChapterSequenceNumber>27</ChapterSequenceNumber>
          <ChapterTitle Language="En">Cancer Immunology, Immunotherapeutics, and Vaccine Approaches</ChapterTitle>
          <ChapterFirstPage>305</ChapterFirstPage>
          <ChapterLastPage>319</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>6</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Ravi</GivenName>
                <GivenName>A.</GivenName>
                <FamilyName>Madan</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff1_27" CorrespondingAffiliationID="Aff1_27">
              <AuthorName DisplayOrder="Western">
                <GivenName>James</GivenName>
                <GivenName>L.</GivenName>
                <FamilyName>Gulley</FamilyName>
              </AuthorName>
              <Contact>
                <Email>gulleyj@mail.nih.gov</Email>
              </Contact>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Jackie</GivenName>
                <FamilyName>Celestin</FamilyName>
              </AuthorName>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Philip</GivenName>
                <GivenName>M.</GivenName>
                <FamilyName>Arlen</FamilyName>
              </AuthorName>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Jeffrey</GivenName>
                <FamilyName>Schlom</FamilyName>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff1_27">
              <OrgDivision>Laboratory of Tumor Immunology and Biology, Medical Oncology Branch</OrgDivision>
              <OrgName>National Cancer Institute</OrgName>
              <OrgAddress>
                <City>Bethesda</City>
                <State>MD</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_27" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Although most patients can be cured of their prostate cancer by initial definitive therapy, up to 40% of patients may have recurrent disease. For these patients, hormonal manipulations may provide initial benefit and chemotherapy has been demonstrated to extend survival when the disease is castration-resistant and metastatic. In spite of these therapeutic approaches, additional therapies are needed. Therapeutic cancer vaccines have been developed using several platforms to enhance immune targeting of prostate cancer cells and have shown promise in early clinical trials. There are several therapeutic cancer vaccine platforms for prostate cancer including vector-based, antigen-presenting cell pulsed and whole tumor-cell vaccines. Several phase II vaccine trials have demonstrated some degree of clinical benefit. Some of these trials, however, have underscored the need for new paradigms to be developed to evaluate the clinical benefit and utility of cancer vaccines. In addition, vaccines have demonstrated compatibility and synergy with standard therapies in both preclinical and clinical models. Several phase III trials with immunotherapies in prostate cancer are in late stages of planning or are ongoing. Future immunotherapy trials should focus on identifying appropriate patient populations most likely to benefit from vaccine therapy and appropriate trial endpoints.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Prostate cancer</Keyword>
            <Keyword>Cancer vaccines</Keyword>
            <Keyword>Immunotherapy</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1">
            <Heading>Rationale for Vaccines in the Treatment of Prostate Cancer</Heading>
            <Para TextBreak="No">Although the US Food and Drug Administration’s (FDA) approval of docetaxel for metastatic castration-resistant prostate cancer (CRPC) in 2004 was a significant advancement in the treatment of prostate cancer, additional therapies are still needed [<CitationRef CitationID="CR1_27">1</CitationRef>, <CitationRef CitationID="CR2_27">2</CitationRef>]. When disease recurs after initial definitive therapy, sequential hormonal manipulations are often used prior to chemotherapy for metastatic CRPC [<CitationRef CitationID="CR3_27">3</CitationRef>]. Therapeutic cancer vaccines have been investigated in both castration-sensitive and castration-resistant disease to determine their role in this sequence of treatments or in combination with existing therapies.</Para>
            <Para TextBreak="No">In many ways, prostate cancer is an ideal candidate for treatments that stimulate the immune system to target cancer cells. In most instances, recurrent prostate cancer is detected by rising levels of serum prostate-specific antigen (PSA) when tumor volume is low and undetectable by imaging [<CitationRef CitationID="CR3_27">3</CitationRef>]. Prostate cancer often grows slowly, allowing time for the immune system to be stimulated and to mount an active immune response [<CitationRef CitationID="CR4_27">4</CitationRef>]. Several gene products are unique to prostate cancer cells, making them suitable targets for immunotherapy [<CitationRef CitationID="CR5_27">5</CitationRef>, <CitationRef CitationID="CR6_27">6</CitationRef>]. Many patients with prostate cancer have low levels of cytolytic T cells capable of recognizing these tumor-associated antigens (TAAs), and this minimal response can be augmented with immune stimulation by therapeutic cancer vaccines [<CitationRef CitationID="CR7_27">7</CitationRef>]. Finally, because the prostate is a nonessential organ, targeting TAAs specific to prostatic tissue is unlikely to have a significant negative clinical impact.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Tumor-Associated Antigens As Targets of Immunotherapy</Heading>
            <Para TextBreak="No">The ideal targets for cancer vaccines are TAAs that are unique to, or are overexpressed in, cancer cells relative to normal tissue. Prostate cancer cells express several such TAAs. PSA is a 34-kD protein uniquely expressed in prostate cancer cells and the nonessential epithelial cells within the prostate, making it the prime target for many prostate cancer vaccines [<CitationRef CitationID="CR8_27">8</CitationRef>, <CitationRef CitationID="CR9_27">9</CitationRef>]. Prostate-specific membrane antigen (PSMA) is a 100-kD transmembrane glycoprotein that is principally expressed in both primary and metastatic prostate cancer cells [<CitationRef CitationID="CR10_27">10</CitationRef>]. An advantageous characteristic of PSMA is that androgen deprivation, which is fundamental to the treatment of prostate cancer, leads to increased PSMA expression [<CitationRef CitationID="CR11_27">11</CitationRef>]. Another TAA that has shown potential as a target of vaccines is prostatic acid phosphotase (PAP), a 102-kD glycoprotein overexpressed in prostate cancer cells that is believed to play a role in disease progression [<CitationRef CitationID="CR12_27">12</CitationRef>, <CitationRef CitationID="CR13_27">13</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>Enhancing Antigen Presentation</Heading>
            <Para TextBreak="No">Developing an effective prostate cancer vaccine presents several challenges. Although prostate cancer provides several TAAs as targets for vaccine therapy, they are commonly weakly immunogenic [<CitationRef CitationID="CR7_27">7</CitationRef>]. An effective vaccine strategy must overcome this obstacle (Table <InternalRef RefID="Tab1">27.1</InternalRef>).<Table Float="Yes" ID="Tab1">
                <Caption Language="En">
                  <CaptionNumber>Table 27.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Modalities that synergize vaccine therapy</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="2">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Method</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Proposed mechanism</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Cytokines</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Traffic APCs to vaccination site; mature and activate APCs</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Androgen- deprivation therapy</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Traffic T cells to the prostate, enhance T-cell repertoire, and decrease immune tolerance of prostate cancer TAAs</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Radiation</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>May upregulate MHC class I antigens, TAAs, and Fas ligand, all of which can enhance cytolytic T-cell activity</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Chemotherapy</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>May enhance MHC class I and TAA expression. Chemotherapy-induced lysis of cells may expose an activated immune response to new TAAs for cytolytic T cells to target</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Anti-CTLA-4 antibody</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>CTLA-4 is expressed on T cells as a way for the immune system to self-regulate immune responses. Blocking this molecule with an antibody can augment the effects of cytolytic T cell activity</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Regulatory T-cell depletion</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Regulatory T cells may suppress T-cell activation and proliferation in response to a vaccine. Using certain chemotherapy agents or monoclonal antibodies, it may be possible to selectively eliminate regulatory T cells and the barriers they pose to immune activation</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
                <tfooter>
                  <SimplePara>
                    <Emphasis Type="Italic">APCs</Emphasis> antigen-presenting cells; <Emphasis Type="Italic">ADT</Emphasis> androgen-deprivation therapy; <Emphasis Type="Italic">TAA</Emphasis> tumor-associated antigen; <Emphasis Type="Italic">MHC</Emphasis> major histocompatibility complex</SimplePara>
                </tfooter>
              </Table>
            </Para>
            <Para TextBreak="No">Cytokines have been found to effectively expand T-cell populations and to enhance the ability of antigen-presenting cells (APCs) to recognize TAAs. In an activated cellular immune response, APCs such as dendritic cells must be activated in order to process antigens, which are then presented to T cells in an immune context, leading to targeted cytolytic T cell-mediated destruction of tumor cells.</Para>
            <Para TextBreak="No">Granulocyte-macrophage colony-stimulating factor (GM-CSF) is commonly used as an adjuvant in immunotherapy. GM-CSF has been shown to increase immune response by stimulating the growth and maturation of APCs and helping them migrate to the vaccination site [<CitationRef CitationID="CR14_27">14</CitationRef>–<CitationRef CitationID="CR16_27">16</CitationRef>]. Some early trials tested GM-CSF as a single agent to see if it had clinical benefit as a nonspecific immune stimulant [<CitationRef CitationID="CR17_27">17</CitationRef>]. More recent studies have shown that injecting GM-CSF at the vaccination site enhances targeted immune responses [<CitationRef CitationID="CR18_27">18</CitationRef>–<CitationRef CitationID="CR20_27">20</CitationRef>]. Other strategies use tumor cells transduced with the gene for GM-CSF to create GM-CSF-secreting whole tumor-cell vaccines [<CitationRef CitationID="CR21_27">21</CitationRef>].</Para>
            <Para TextBreak="No">Another mechanism to enhance APC activation of T cells is the use of costimulatory molecules. During the critical stage of antigen presentation, APCs present the antigen within its major histocompatibility complex (MHC) to the T cell via the T-cell receptor. The interaction of other accessory, or costimulatory, molecules is also necessary for T-cell activation, especially when the TAA is weakly immunogenic. The absence of costimulatory molecules with such weak antigens could lead to T-cell anergy and even apoptosis [<CitationRef CitationID="CR22_27">22</CitationRef>]. In poxviral-based cancer vaccines, transgenes for costimulatory molecules can be included with the TAA transgene within the vector. When such a poxviral-based vaccine infects APCs, it leads to expression of the TAA within the MHC for presentation to T cells. The vaccine’s effects can be enhanced by including a transgene encoded for one or more costimulatory molecules, which are then expressed on the APC that is presenting the TAA [<CitationRef CitationID="CR18_27">18</CitationRef>, <CitationRef CitationID="CR19_27">19</CitationRef>, <CitationRef CitationID="CR22_27">22</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec4">
            <Heading>Vaccines as Part of Combination Therapy for Prostate Cancer</Heading>
            <Para TextBreak="No">Vaccine therapies are increasingly being investigated in combination with other therapies, potentially enhancing the treatment of both early- and late-stage prostate cancer. Some conventional therapies may actually enhance both the immune profile of tumors and cytolytic T-cell activity [<CitationRef CitationID="CR23_27">23</CitationRef>]. This can be particularly valuable in prostate cancer where, depending on the stage of disease, androgen-deprivation therapy (ADT), radiation, and chemotherapy all play a role.</Para>
            <Section2 ID="Sec5">
              <Heading>Androgen-Deprivation Therapy</Heading>
              <Para TextBreak="No">Patients with recurrent prostate cancer treated with hormonal manipulation alone often have asymptomatic disease. Here, the goal of therapy is to delay symptomatic disease that may require more aggressive therapies with greater toxicity [<CitationRef CitationID="CR3_27">3</CitationRef>]. Evidence suggests that ADT can enhance immune responses in these patients [<CitationRef CitationID="CR24_27">24</CitationRef>]. One study evaluated prostatic tissue before and after initiating ADT. T-cell infiltration of the prostate was seen within 1–3 weeks, and T cells isolated from the prostate exhibited a restricted receptor, indicating a local oligoclonal response [<CitationRef CitationID="CR25_27">25</CitationRef>]. In another study, the androgen receptor antagonist flutamide curtailed testosterone’s potential for T-cell inhibition [<CitationRef CitationID="CR26_27">26</CitationRef>]. Other studies indicate that ADT decreases immune tolerance to prostate TAAs, promotes growth of the thymus (where T cells are produced), and enhances the T-cell repertoire [<CitationRef CitationID="CR27_27">27</CitationRef>–<CitationRef CitationID="CR29_27">29</CitationRef>]. All of these findings make combination therapy with ADT and vaccines an active and promising area of research.</Para>
            </Section2>
            <Section2 ID="Sec6">
              <Heading>Radiation Therapy</Heading>
              <Para TextBreak="No">Local radiation of the prostate can be part of the initial definitive therapy of prostate cancer or part of a salvage regimen if the disease recurs after radical prostatectomy [<CitationRef CitationID="CR30_27">30</CitationRef>]. One potential drawback of radiation therapy is that some cells at the center of larger tumor masses may receive sublethal amounts of radiation, allowing them to survive initial definitive therapy. Preclinical studies have demonstrated that low levels of radiation can upregulate certain membrane antigens, including MHC class I antigens, TAAs, and Fas ligand, which can enhance cytolytic T-cell activity potentially induced by a vaccine [<CitationRef CitationID="CR31_27">31</CitationRef>–<CitationRef CitationID="CR33_27">33</CitationRef>]. These effects of radiation on prostate cancer cells have led to studies of vaccines in the adjuvant setting, where patients with high-risk disease may benefit from enhanced immune surveillance [<CitationRef CitationID="CR34_27">34</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec7">
              <Heading>Combination Chemotherapy</Heading>
              <Para TextBreak="No">Chemotherapy is a noncurative treatment for most metastatic cancers, including prostate cancer, making its combination with vaccine potentially appealing if it can delay disease progression and increase overall survival. Certain chemotherapy agents have been shown to enhance expression of TAAs and MHC class I, both of which can make cancer cells more amenable to vaccine-induced cytolytic T-cell activity [<CitationRef CitationID="CR35_27">35</CitationRef>–<CitationRef CitationID="CR38_27">38</CitationRef>]. Additionally, an activated immune response triggered by a vaccine in the setting of chemotherapy-induced cell lysis may expose the immune system to a variety of antigens, leading to an immune response against TAAs not specifically targeted by the vaccine (antigen cascade) [<CitationRef CitationID="CR34_27">34</CitationRef>, <CitationRef CitationID="CR39_27">39</CitationRef>]. Preclinical studies have further demonstrated other effects of chemotherapy that may increase the benefits of immune-mediated therapy. Doxorubicin has been shown to increase the number and activity of macrophages, while in vitro studies of docetaxel have demonstrated increases in proinflammatory cytokines [<CitationRef CitationID="CR40_27">40</CitationRef>–<CitationRef CitationID="CR42_27">42</CitationRef>]. Docetaxel has also been shown to enhance CD8 responses to vaccine, augmenting immune responses to TAAs specifically targeted by the vaccine in addition to other TAAs as part of an antigen cascade. Finally, docetaxel combined with vaccine has been shown to be more effective than either treatment alone in a murine tumor treatment model [<CitationRef CitationID="CR39_27">39</CitationRef>]. Other chemotherapeutic agents such as cyclophosphamide may enhance immune response and the benefits of vaccine by reducing the levels and inhibitory effects of regulatory T cells (Tregs) [<CitationRef CitationID="CR43_27">43</CitationRef>, <CitationRef CitationID="CR44_27">44</CitationRef>].</Para>
              <Para TextBreak="No">The greatest potential drawback of combining chemotherapy with vaccine is that the cytotoxic effects of chemotherapy may kill the immune cells generated by the vaccine. However, recent clinical evidence indicates that some combinations of vaccine and chemotherapy may be compatible. A phase II trial combined docetaxel with a poxviral-based vaccine targeting PSA and compared the combination to the vaccine alone in patients with metastatic CRPC. After 3 months on study, the two groups showed equal immune responses to the vaccine, indicating that chemotherapy did not depress immune response to the vaccine [<CitationRef CitationID="CR45_27">45</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec8">
              <Heading>Sequential Chemotherapy</Heading>
              <Para TextBreak="No">There is mounting clinical evidence that vaccines may initiate a dynamic immune response to TAAs that could be augmented by subsequent chemotherapy. A phase I study treated 17 patients with a plasmid/microparticle-based vaccine targeting cytochrome P450B1, which is overexpressed in some tumors. The five patients who developed an immune response also had a longer than expected clinical response to salvage chemotherapy, some lasting up to 12 months [<CitationRef CitationID="CR46_27">46</CitationRef>]. In another study in nonsmall cell lung cancer, in which 29 patients were treated with an adenovirus-based vaccine targeting P53, a higher than expected proportion of patients (61.9%) had objective response to salvage chemotherapy initiated after vaccine treatments [<CitationRef CitationID="CR47_27">47</CitationRef>]. This phenomenon has also been seen in a prostate cancer trial. Of 34 patients with metastatic CRPC treated with the whole tumor-cell vaccine GVAX, 13 patients who went on to receive a taxane-based chemotherapy had a mean overall survival of 35.2 vs. 17.2 months for those who did not receive chemotherapy [<CitationRef CitationID="CR48_27">48</CitationRef>]. While these studies suggest a benefit for sequential vaccine followed by chemotherapy, further randomized studies designed to evaluate these treatments in these particular sequences are needed.</Para>
            </Section2>
            <Section2 ID="Sec9">
              <Heading>Anti-CTLA-4</Heading>
              <Para TextBreak="No">For most weak antigens such as TAAs, a signal from the T-cell receptor is insufficient to optimally activate the T cell [<CitationRef CitationID="CR49_27">49</CitationRef>]. A second immune-enhancing signal mediated through CD28 on the T cell binding to B7 on the APC is required to activate the T cell specific for the target antigen. CTLA-4 is expressed on the surface of the T cell within 2–3 days following activation and also binds to B7. This high-affinity binding generates a negative signal, effectively halting an ongoing immune response. The key regulatory role of CTLA-4 is underscored in CTLA-4 knockout mice that cannot turn off immune responses and live only 2–3 weeks before succumbing to massive infiltration of organs by unchecked growth of autoreactive T cells [<CitationRef CitationID="CR50_27">50</CitationRef>]. Thus, antagonistic antibodies that prevent CTLA-4 signaling may enhance T-cell expansion.</Para>
              <Para TextBreak="No">Studies have shown the rejection of established tumors in murine models demonstrating the therapeutic potential of CTLA-4 blockade [<CitationRef CitationID="CR51_27">51</CitationRef>]. However, CTLA-4 blockade may also potentiate the growth of inhibitory Tregs. A recent study showed that anti-CTLA-4 monotherapy proportionally increased Tregs and effector T cells (Teffs) within the tumor, whereas CTLA-4 blockade with vaccine increased Teffs more than Tregs and, unlike CTLA-4 blockade alone, induced tumor rejection [<CitationRef CitationID="CR52_27">52</CitationRef>]. Furthermore, the quantity of tumor-specific Teffs may not be as important as the functional ability of those cells, for only high-avidity tumor-specific T cells can efficiently kill tumor cells [<CitationRef CitationID="CR53_27">53</CitationRef>]. Anti-CTLA-4 antibodies combined with vaccine not only increase the number of tumor-specific Teffs over vaccine alone, but, to a much greater magnitude, also increase the avidity of those T cells [<CitationRef CitationID="CR54_27">54</CitationRef>]. Several anti-CTLA-4 antibodies have been developed and preclinical models have demonstrated increased antitumor activity in the murine model, which can be enhanced by vaccines [<CitationRef CitationID="CR54_27">54</CitationRef>–<CitationRef CitationID="CR56_27">56</CitationRef>]. Several studies have evaluated anti-CTLA-4 antibodies in combination with a vaccine in the treatment of different malignancies, including prostate cancer [<CitationRef CitationID="CR57_27">57</CitationRef>–<CitationRef CitationID="CR59_27">59</CitationRef>].</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec10">
            <Heading>Vaccine Approaches</Heading>
            <Para TextBreak="No">Several different types of prostate cancer vaccine are currently in clinical development. Three vaccine types in particular represent different strategies that have been employed extensively in the clinical setting (Table <InternalRef RefID="Tab2">27.2</InternalRef>).<Table Float="Yes" ID="Tab2">
                <Caption Language="En">
                  <CaptionNumber>Table 27.2</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Three main vaccine approaches</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="2">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Vaccine type</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Mechanism of action</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Vector-based</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Poxviruses containing transgenes for TAAs and costimulatory molecules are injected subcutaneously. They infect APCs, leading to presentation of TAAs and costimulatory molecules in an immune context to T cells. These T cells are then activated and target TAAs on cancer cells</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>APC-pulsed</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>APCs are removed from a patient’s circulation and exposed ex vivo to a specific TAA and cytokines for activation and maturation. These activated APCs are then re-infused into the blood stream where they activate T cells, leading to a targeted immune response. These treatments are patient-specific</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Whole tumor- cell</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Multiple allogeneic tumor cell lines are cultured ex vivo and then treated with lethal irradiation. The cells are then injected into subcutaneous sites where APCs process TAAs and activate T cells. Tumor cells may be transfected to express a cytokine such GM-CSF or other adjuvants may be used. This type of treatment is not patient-specific and does not define which TAA the T cells will target</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
                <tfooter>
                  <SimplePara>
                    <Emphasis Type="Italic">APCs</Emphasis> antigen-presenting cells; <Emphasis Type="Italic">TAA</Emphasis> tumor-associated antigen</SimplePara>
                </tfooter>
              </Table>
            </Para>
            <Section2 ID="Sec11">
              <Heading>Vector-Based Vaccines</Heading>
              <Para TextBreak="No">The goal of targeted immune therapies is to focus the immune system on weakly immunogenic TAAs, such as PSA. Poxviral vaccines are able to deliver transgenes for TAAs to APCs, where they are then processed and expressed on the APC surface within the MHC, leading to T-cell activation. Recombinant poxviral vectors are developed by first generating the recombinant plasmid containing the transgenes that will ultimately code for the selected proteins, in this case TAAs. The plasmid is then transfected into a permissive eukaryotic cell line, which is subsequently infected by wild-type poxviruses. As the poxviruses reproduce within the cell, a small proportion will contain the recombinant plasmid. Expression of certain markers included within the plasmid can help identify which poxviruses contain the recombinant plasmid. These particular poxviral vectors can then be isolated and amplified for use as a cancer vaccine [<CitationRef CitationID="CR60_27">60</CitationRef>].</Para>
              <Para TextBreak="No">There are many advantages to using a poxvirus as a delivery mechanism for cancer vaccines. Injecting the poxvirus into subcutaneous tissue results in an inflammatory response against foreign proteins. The ensuing chemotaxis sends APCs to the injection site. As a result, the recombinant protein product of the transgene contained within the poxvirus vector is significantly more immunogenic than the naked protein with an adjuvant [<CitationRef CitationID="CR61_27">61</CitationRef>, <CitationRef CitationID="CR62_27">62</CitationRef>]. Several other factors make poxviruses ideal delivery vehicles for vaccines. Poxviruses are extremely effective at infecting APCs, especially dendritic cells. When costimulatory molecules are also included within the poxvirus genome, the capability of cells to act as APCs is greatly enhanced [<CitationRef CitationID="CR60_27">60</CitationRef>, <CitationRef CitationID="CR63_27">63</CitationRef>–<CitationRef CitationID="CR65_27">65</CitationRef>]. The large poxviral genome allows for the transfer of a large amount of DNA into host cells, which can include transgenes for costimulatory molecules in addition to multiple antigens [<CitationRef CitationID="CR60_27">60</CitationRef>, <CitationRef CitationID="CR66_27">66</CitationRef>]. Vaccinia has been used safely in humans for over five decades, and all genes transported by the poxvirus are processed in the cell cytoplasm, eliminating the possibility of integration within or disruption of the host DNA. Furthermore, only poxviral enzymes are used in translation. Finally, poxviral vaccines are easily administered subcutaneously and require very little preparation.</Para>
              <Para TextBreak="No">A phase I study of a poxviral vaccine targeting PSA enrolled 42 patients with metastatic CRPC at five escalating doses. Patients were treated monthly for 3 months with recombinant vaccinia (rV)-PSA (containing the transgene for PSA). A cohort of patients also received GM-CSF at the vaccination site as part of an extension phase. The vaccine was well tolerated and reached no dose-limiting toxicity. The most common side effects were transient fever, fatigue, and injection-site reactions. In addition, three of five evaluable patients had increases in PSA-specific T cells, indicating that the vaccine had generated a targeted immune response [<CitationRef CitationID="CR67_27">67</CitationRef>].</Para>
              <Para TextBreak="No">A crucial factor in the effectiveness of poxviral vaccines is that different species of poxviruses allow for their sequential use for maximal immune response to transgene TAAs and clinical benefit. This feature was utilized to improve the poxviral vaccine targeting PSA [<CitationRef CitationID="CR60_27">60</CitationRef>]. Vaccinia is highly immunogenic and induces a robust immune response upon initial vaccination. Subsequent exposure to vaccinia, however, results in rapid neutralization by the host antibodies targeting viral coat proteins, which greatly reduces the ability of the vaccinia-based vaccine to infect APCs [<CitationRef CitationID="CR67_27">67</CitationRef>–<CitationRef CitationID="CR69_27">69</CitationRef>]. After priming with vaccinia, boosting with a second poxviral vector is required to sustain the immune response. Fowlpox-based vectors, which are also capable of infecting APCs, produce only early viral gene products, and not viral coat proteins. This characteristic prevents their replication in mammals and also prevents the host immune system from making significant quantities of neutralizing antibodies against fowlpox-based vaccines [<CitationRef CitationID="CR70_27">70</CitationRef>, <CitationRef CitationID="CR71_27">71</CitationRef>]. This diversified prime and boost strategy was initially demonstrated in preclinical models and then in phase I human studies [<CitationRef CitationID="CR71_27">71</CitationRef>, <CitationRef CitationID="CR72_27">72</CitationRef>]. A subsequent randomized trial targeting PSA showed that patients who received a vaccinia (rV-PSA) prime followed by fowlpox (rF-PSA) boosts had increased time to PSA progression compared with patients who received fowlpox alone or fowlpox before vaccinia [<CitationRef CitationID="CR73_27">73</CitationRef>, <CitationRef CitationID="CR74_27">74</CitationRef>].</Para>
              <Para TextBreak="No">Several trials have employed a poxviral vaccine targeting PSA in combination with conventional therapies. Based on preclinical data suggesting that radiation may make tumor cells more susceptible to immune-mediated killing [<CitationRef CitationID="CR31_27">31</CitationRef>, <CitationRef CitationID="CR32_27">32</CitationRef>], a study randomized 30 patients with localized prostate cancer 2:1 favoring vaccine plus radiation over radiation alone. Patients received an admixed priming vaccination [rV-PSA plus recombinant vaccinia containing the transgene for the costimulatory molecule B7.1 (rV-B7.1)]. Recombinant fowlpox (rF)-PSA was injected monthly as a booster, for a total of eight vaccines. All vaccines were given with low-dose IL-2 and GM-CSF as an immune adjuvant. Radiation therapy was given between months 4 and 6. Seventeen of 19 patients in the combination treatment arm completed all eight vaccinations and had a ≥3-fold increase in PSA-specific T cells after radiation, compared to no change in T cells in the radiation-only group (<Emphasis Type="Italic">p</Emphasis>= 0.0005) [<CitationRef CitationID="CR34_27">34</CitationRef>]. A follow-up study showed that metronomic doses of IL-2 produced similar levels of immune response to vaccine, with virtually none of the side effects associated with high-dose IL-2 [<CitationRef CitationID="CR75_27">75</CitationRef>]. A randomized phase II study is currently evaluating a next-generation poxviral vaccine containing three costimulatory molecules (see PSA-TRICOM below) in combination with Samarium-153 (Sm-153) vs. Sm-153 alone in patients with CRPC metastatic predominantly to bone. Sm-153, FDA-approved for palliation of pain in this setting, is composed of radioactive samarium and a tetraphosphate chelator that binds to metastatic lesions in bone. The goal of this study is to evaluate the benefits of low-level radiation to metastatic tumor sites provided by locally binding Sm-153 in the setting of an active immune response [<CitationRef CitationID="CR76_27">76</CitationRef>].</Para>
              <Para TextBreak="No">Another trial comparing hormonal therapy and a poxviral vaccine targeting PSA randomized 42 patients with nonmetastatic CRPC (stage D0.5) to initial treatment with nilutamide (an androgen receptor antagonist) or vaccine. Again, the vaccine regimen consisted of a prime with an admixture of rV-PSA and rV-B7.1 followed by monthly boosts of rF-PSA. Patients who had a rising PSA on either treatment, but no evidence of metastatic disease on imaging, could receive the other treatment in addition to their primary therapy. For patients randomized to the vaccine arm, median time to PSA progression was 9.9 months compared with 7.6 months for patients randomized to nilutamide. The results of this study suggested a benefit from combination therapy, especially when vaccine was started earlier. For the eight patients who were randomized to nilutamide and had vaccine added, median time to progression was 15.9 months after enrollment and 5.2 months after starting the combination. For the 12 patients who had vaccine first and nilutamide added, median time to progression was 25.9 months from enrollment and 13.9 months after starting the combination [<CitationRef CitationID="CR77_27">77</CitationRef>]. A subsequent survival analysis indicated a trend to improved overall survival in patients randomized to the vaccine arm compared with the nilutamide arm (median overall survival 5.1 vs. 3.4 years; <Emphasis Type="Italic">p</Emphasis>= 0.13). The survival benefit appeared to be greatest in patients with less aggressive disease (Gleason score ≤ 7; <Emphasis Type="Italic">p</Emphasis>= 0.033), lower PSA (&lt;20 μg/mL; <Emphasis Type="Italic">p</Emphasis> = 0.013), and previous radiation therapy (<Emphasis Type="Italic">p</Emphasis>= 0.018). This survival trend associated with vaccine given earlier in treatment was also seen in patients who received both agents in combination. For patients who received vaccine first and had nilutamide added, the median overall survival was 6.2 vs. 3.7 years in patients randomized to nilutamide who had vaccine added (<Emphasis Type="Italic">p</Emphasis>= 0.045) [<CitationRef CitationID="CR78_27">78</CitationRef>]. A trial is currently accruing to confirm the benefits of androgen receptor antagonist (flutamide) in combination with a second-generation poxviral vaccine targeting PSA vs. androgen receptor antagonist alone in patients with nonmetastatic CRPC [<CitationRef CitationID="CR79_27">79</CitationRef>].</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec12">
            <Heading>PSA-TRICOM</Heading>
            <Para TextBreak="No">Further preclinical research with poxviral-based vaccines indicated that multiple costimulatory molecules could be delivered within a single vector. A construct containing a triad of costimulatory molecules called TRICOM includes transgenes for B7.1, intracellular adhesion molecule (ICAM)-1, and leukocyte function-associated antigen (LFA)-3. In vitro and in vivo studies have shown that TRICOM significantly enhances T-cell activation relative to just one or two costimulatory molecules [<CitationRef CitationID="CR18_27">18</CitationRef>, <CitationRef CitationID="CR19_27">19</CitationRef>, <CitationRef CitationID="CR80_27">80</CitationRef>]. A phase I study in patients with metastatic CRPC has shown that an rV-PSA-TRICOM prime followed by monthly boosts of rF-PSA-TRICOM was well tolerated. Furthermore, patients treated with PSA-TRICOM who were evaluable for immune response had an increase in PSA-specific T cells after treatment, and 9 of 15 patients had decreases in PSA velocity [<CitationRef CitationID="CR81_27">81</CitationRef>].</Para>
            <Para TextBreak="No">A pair of phase II studies has provided initial evidence for improved overall survival in patients treated with PSA-TRICOM. An industry-sponsored phase II trial employed PSA-TRICOM in 125 patients with metastatic CRPC and Gleason scores ≤7, randomized 2:1 in favor of vaccine vs. an empty fowlpox vector as control. Patients randomized to receive vaccine were given an rV-PSA-TRICOM prime with monthly boosts of rF-PSA-TRICOM, while control patients were given subcutaneous injections of fowlpox. The primary endpoint of the study was time to progression as measured by new or expanding lesions on bone scan and CT scan, respectively. The study failed to meet this primary endpoint, but median overall survival was 24.4 months in the vaccine arm compared with 16.3 months in the control arm, suggesting that although disease progression occurred at similar times in both groups, there appeared to be a long-term benefit for some patients treated with PSA-TRICOM [<CitationRef CitationID="CR82_27">82</CitationRef>].</Para>
            <Para TextBreak="No">In another phase II study of PSA-TRICOM at the National Cancer Institute (NCI), 32 patients with metastatic CRPC were treated with an rV-PSA-TRICOM prime and monthly boosts of rF-PSA-TRICOM. In that trial, 47% of patients had a decrease in PSA velocity, 38% had a PSA decline, 13 of 29 evaluable patients had a &gt;2-fold increase in PSA-specific T cells, and five patients had a &gt;6-fold increase in PSA-specific T cells which was associated with a trend to improved overall survival (<Emphasis Type="Italic">p</Emphasis>= 0.055) [<CitationRef CitationID="CR83_27">83</CitationRef>]. The median overall survival of all patients enrolled was 26.6 months, which compares favorably to trials leading to approval for docetaxel in metastatic CRPC, where median survival was approximately 18 months [<CitationRef CitationID="CR1_27">1</CitationRef>, <CitationRef CitationID="CR2_27">2</CitationRef>]. The overall survival of all patients was also compared with survival as predicted by the Halabi nomogram. The Halabi nomogram predicts survival based on seven baseline parameters (accounting for disease volume and aggressiveness) that were found to be significant based on an analysis of 1,101 patients with metastatic CRPC treated with chemotherapy or second-line hormonal therapy in Cancer and Leukemia Group B studies between 1991 and 2001 [<CitationRef CitationID="CR84_27">84</CitationRef>]. For patients with a predicted survival of &lt;18 months, there was only a modest improvement after treatment with PSA-TRICOM (14.6 vs. 12.3 months). When patients with better prognostic features (i.e., a predicted survival ≥18 months) were evaluated, there was a more pronounced improvement after treatment with PSA-TRICOM vs. that predicted with standard therapy, with a median overall survival not reached at 44.6 months vs. Halabi-predicted overall survival of 20.9 months. Although this was a small study, these results provide evidence that metastatic CRPC patients treated with a vaccine have an overall survival similar to the predicted survival of patients treated with chemotherapy or second-line hormone therapy. Furthermore, these data suggest that patients with more indolent disease may receive greater benefit from vaccine-mediated therapy than from chemotherapy or second-line hormone therapy. Follow-up studies are currently being designed to further test this hypothesis [<CitationRef CitationID="CR83_27">83</CitationRef>].</Para>
            <Section2 ID="Sec13">
              <Heading>Antigen-Presenting Cell Vaccines: Sipuleucel-T</Heading>
              <Para TextBreak="No">An alternative approach to vaccine therapy relies not on in vivo antigen stimulation, but on removing APCs, stimulating them with an antigen ex vivo, and then injecting the stimulated APCs back into the blood stream. The sipuleucel-T vaccine (Provenge®; Dendreon Corp., Seattle, WA) is developed from peripheral blood mononuclear cells exposed in vitro to a prostate cancer antigen in a process that takes under 48 h. Dendritic cells, T cells, B cells, and natural killer cells are selectively collected from patients by leukapheresis. These APCs are then processed and exposed ex vivo to PA2024, a recombinant fusion protein of human PAP and GM-CSF, which leads to APC activation and maturation. The excess antigen is then removed for the solution and the APCs are concentrated in 250 cc of Lactated Ringer’s that can then be infused into the patient [<CitationRef CitationID="CR85_27">85</CitationRef>, <CitationRef CitationID="CR86_27">86</CitationRef>].</Para>
              <Para TextBreak="No">A phase I study demonstrated the safety and efficacy of this approach in 12 evaluable patients with metastatic CRPC. Patients were given two infusions 1 month apart of autologous APCs exposed to PA2024 ex vivo, as described above. After the infusions, patients were given three escalating doses of subcutaneous PA2024 (0.3, 0.6, and 1.0 mg/injection) at 1-month intervals. The vaccine was well tolerated, with the main side effects being fevers, chills, fatigue, and injection-site reactions. Three patients had PSA declines, and T-cell proliferation assays demonstrated up to a 10-fold increase from baseline in response to GM-CSF and PAP. The injections of PA2024, however, were not found to enhance cellular immune response [<CitationRef CitationID="CR87_27">87</CitationRef>].</Para>
              <Para TextBreak="No">A phase I/II study was also done in patients with nonmetastatic CRPC. Twelve patients were enrolled on the phase I-dose escalation portion (maximum doses 2 × 10<Superscript>9</Superscript> nucleated cells/m<Superscript>2</Superscript>), and 19 patients were added in the phase II portion. Infusions were administered at weeks 0, 4, and 8 for all patients and at week 24 for patients who continued to have stable disease at that point. The infusions were well tolerated at all dose levels, with fever being the most frequent adverse event. Six patients had a &gt;25% PSA decline, and three of these six had declines &gt;50%. The median time to progression based on PSA was 12 weeks on phase I and 29 weeks on phase II, suggesting that patients did better with higher doses. An immune response to PAP was seen in 38% of patients, which also correlated with improved time to progression [<CitationRef CitationID="CR88_27">88</CitationRef>]. In another phase II trial in metastatic CRPC, 19 evaluable patients were given infusions of the sipuleucel-T vaccine on weeks 0 and 2 and injections of PA2024 (0.5 mg subcutaneously in each thigh) on weeks 4, 8, and 12. The treatment was well tolerated with only rare grade 3/4 infusion-associated toxicities (chills, fatigue, fever, malaise, emesis, dyspnea, and tachycardia). Three patients on this study had a &gt;25% decrease in PSA, including one patient whose PSA dropped from 221 ng/mL to undetectable levels at 24 weeks. Median time to progression for all patients was 16.9 weeks. An immune analysis again showed increased responsiveness to PA2024 in vitro 4 weeks after initial treatment. The patient with the most significant drop in PSA had an increased immune response for 96 weeks after enrollment [<CitationRef CitationID="CR89_27">89</CitationRef>].</Para>
              <Para TextBreak="No">Two phase III placebo-controlled studies were done in patients with metastatic CRPC randomized 2:1 in favor of the sipuleucel-T vaccine, and results were encouraging but not definitive. In both studies, sipuleucel-T was administered on weeks 0, 2, and 4 and crossover was allowed for patients who progressed (defined as new lesions on imaging or increased pain) after 8 weeks. The primary endpoint of both studies was time to progression [<CitationRef CitationID="CR90_27">90</CitationRef>, <CitationRef CitationID="CR91_27">91</CitationRef>]. The first trial to report results enrolled 82 patients on treatment and 45 patients on placebo (34 of whom would go on to receive sipuleucel-T as part of the crossover component). This trial failed to meet its primary endpoint, although time to progression favored the patients randomized to sipuleucel-T (16.6 vs. 10 weeks; <Emphasis Type="Italic">p</Emphasis>= 0.052). Overall survival, however, showed a 4.5-month improvement in patients randomized to sipuleucel-T (25.9 vs. 21.4 months; <Emphasis Type="Italic">p</Emphasis>= 0.01). This overall survival benefit was even greater at 36 months, with estimated survival of 34% for the sipuleucel-T group vs. 11% for the placebo group (<Emphasis Type="Italic">p</Emphasis>= 0.005) [<CitationRef CitationID="CR90_27">90</CitationRef>]. When this phase III trial did not meet its primary endpoint of time to progression, but before survival benefit was seen, the second phase III trial was terminated early. When the 98 patients (65 treated with sipuleucel-T, 33 on placebo) in this second study were analyzed, no time to progression or survival benefit was seen [<CitationRef CitationID="CR86_27">86</CitationRef>, <CitationRef CitationID="CR91_27">91</CitationRef>]. Given these varied results, the FDA has elected to await the results of an ongoing phase III trial that has already enrolled over 500 patients with metastatic CRPC. The endpoint of this study is overall survival, and it will be analyzed when 360 deaths have occurred. An interim analysis is expected in the fourth quarter of 2008 [<CitationRef CitationID="CR92_27">92</CitationRef>]. There is also an ongoing phase II study using this vaccine in the neoadjuvant setting, prior to radical prostatectomy in men with localized disease [<CitationRef CitationID="CR93_27">93</CitationRef>] (See <ExternalRef>
                  <RefSource>Chapter 28</RefSource>
                  <RefTarget Address="10.1007/978-1-60327-829-4_28" TargetType="DOI"/>
                </ExternalRef>: Sipuleucel-T for detailed information on this vaccine).</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec14">
            <Heading>Whole Tumor-Cell Vaccines</Heading>
            <Section2 ID="Sec15">
              <Heading>GVAX</Heading>
              <Para TextBreak="No">GVAX (Cell Genesys Inc., South San Francisco, CA) is an allogeneic cellular immunotherapy that is not patient-specific. GVAX consists of two prostate cancer cell lines (LNCaP and PC-3, derived from metastatic prostate cancer lesions) that have been transfected with a human gene that encodes GM-CSF. (This transfection was initially accomplished using a retroviral vector, but subsequent studies showed that an adenovirus vector results in increased secretion of GM-CSF.) After transfection, the cells are exposed to lethal levels of gamma radiation that denatures DNA and prevents cellular replication, while allowing GM-CSF secretion to continue. When injected into the patient, the cells cause a localized immune response, with the secreted GM-CSF as an adjuvant facilitating the attraction, maturation, and activation of APCs. These APCs then process TAAs and activate CD4<Superscript>+</Superscript> and CD8<Superscript>+</Superscript> T cells in local lymph nodes, leading to an antigen-specific T-cell response [<CitationRef CitationID="CR21_27">21</CitationRef>]. Since each patient’s immune system processes whole tumor cells differently, the TAAs targeted may vary from patient to patient.</Para>
              <Para TextBreak="No">A phase I study first evaluated the concept of whole tumor-cell vaccines using autologous cells from 11 men who were found to have metastatic disease at radical prostatectomy. They were treated with autologous prostate cancer cells transfected to secrete GM-CSF and then irradiated. Eight of 11 patients had sufficient in vitro expansion of cultured cells to allow for treatment. The autologous cells were well tolerated, with injection-site reactions and flu-like symptoms the most common side effects. Although some patients showed evidence of B-cell and T-cell responses, the use of autologous cells proved to be too inefficient for further study [<CitationRef CitationID="CR94_27">94</CitationRef>].</Para>
              <Para TextBreak="No">Subsequent trials utilized the GM-CSF-secreting PC-3 and LNCaP cell lines. A phase I/II trial was done in patients with rising PSA after radical prostatectomy (castration-sensitive, nonmetastatic, or stage D0 prostate cancer). All 21 patients enrolled completed the course of 8 weekly intradermal injections (1.2 × 10<Superscript>8</Superscript> cells) of the whole tumor-cell vaccine (all doses contained equal parts of each cell line). Again, flu-like symptoms and injection-site reactions were the most common side effects. Clinically, one patient had a &gt;50% PSA decline and 17 of 21 patients had decreases in PSA velocity 20 weeks after completing therapy (<Emphasis Type="Italic">p</Emphasis>&lt; 0.001). From an immunologic standpoint, biopsies of the vaccination site showed that APCs had been recruited locally, while patients also had elevated levels of antibodies targeting five different antigens found on the allogeneic tumor cells. In addition, the best PSA response correlated with a high-titer antibody response to an LNCaP antigen [<CitationRef CitationID="CR95_27">95</CitationRef>].</Para>
              <Para TextBreak="No">Two dose-escalation studies of GVAX have been conducted. One study employed 5.0 × 10<Superscript>8</Superscript> cells as a priming dose and 1.0 × 10<Superscript>8</Superscript> as a booster every 2 weeks for up to 6 months. Twenty-one patients enrolled on study had nonmetastatic CRPC and 34 patients had asymptomatic metastatic CRPC. For patients with nonmetastatic CRPC, median time to PSA progression and progression of lesions on bone scan was 3.9 and 5.9 months, respectively. For patients with metastatic CRPC, time to PSA progression and progression of lesions on bone scan was 2.6 and 3.0 months, respectively. In the metastatic CRPC group, the last ten patients enrolled received 3.0 × 10<Superscript>8</Superscript> instead of 1 × 10<Superscript>8</Superscript> as a biweekly booster. The overall survival of the metastatic CRPC patients was 26.2 months; however, patients who received the high-dose booster lived 34.9 months compared with 24.0 months for patients who received the lower dose, indicating that benefit may increase with higher doses of cells [<CitationRef CitationID="CR48_27">48</CitationRef>].</Para>
              <Para TextBreak="No">In a separate study of GVAX, 80 patients with metastatic CRPC were treated for 6 months at three different dose levels and schedules: low (1.0 × 10<Superscript>8</Superscript> or 2.0 × 10<Superscript>8</Superscript> monthly), medium (2.0 × 10<Superscript>8</Superscript> biweekly), or high (3.0 × 10<Superscript>8</Superscript> biweekly or 5.0 × 10<Superscript>8</Superscript> priming dose with 3.0 × 10<Superscript>8</Superscript> biweekly). A maximum tolerated dose was not reached and the previously seen side effects of flu-like symptoms, headache, and injection-site reactions were reported. One patient had a &gt;50% decline in PSA lasting 3.9 months, and 15 patients had a stable PSA (&lt;50% decline to &lt;25% increase) for at least 90 days. No significant differences were seen in PSA responses among the different dose levels. Times to PSA progression were 2.8 months (low doses), 2.2 months (medium dose), and 2.5 months (high doses). Although 35% of all patients had stable disease, none had an objective response. Overall survival, however, was greater in the high-dose cohort: 35 vs. 23.1 months in patients treated with low doses and 20 months in those treated with the medium dose. Survival in the high-dose cohort also compared favorably to the Halabi predicted survival of 22.0 months [<CitationRef CitationID="CR84_27">84</CitationRef>, <CitationRef CitationID="CR96_27">96</CitationRef>]. A study has also been done combining GVAX with the anti-CTLA-4 monoclonal antibody ipilimumab. Dosing of GVAX for this study was 5.0 × 10<Superscript>8</Superscript> as a prime, then 3.0 × 10<Superscript>8</Superscript> biweekly for 24 weeks, with escalating monthly doses of ipilimumab (0.3, 1, 3, or 5 mg/kg) for 24 weeks. In addition to injection-site reactions and flu-like symptoms, the combination was also associated with immune-mediated side effects, notably hypophysitis, in five of six patients at the higher dose levels. Immune breakthrough events correlated with clinical response as PSA declines &gt; 50% were seen in these five patients, with durations of 6.7–23.1 months. Four patients also had stable bone scans for at least 3 months. Immunologic responses in the form of dendritic-cell and T-cell activation were also seen at the higher dose levels. Based on these preliminary findings, an expansion cohort of 16 patients will be enrolled to provide further safety and efficacy data [<CitationRef CitationID="CR57_27">57</CitationRef>, <CitationRef CitationID="CR58_27">58</CitationRef>].</Para>
              <Para TextBreak="No">Two phase III trials with GVAX are currently underway. The endpoint for both studies is overall survival [<CitationRef CitationID="CR97_27">97</CitationRef>]. VITAL-1, a clinical trial that opened in 2004, is comparing GVAX to standard-of-care docetaxel and prednisone in patients with asymptomatic metastatic CRPC. VITAL-1 completed enrollment with about 600 patients. In 2005, VITAL-2 was opened for patients with metastatic CRPC who had disease-related pain. The 600 patients in this study were randomized to either GVAX and docetaxel or docetaxel and prednisone. A recent report indicated that this study has been stopped due to unforeseen toxicity in the vaccine plus chemotherapy arm; this is now being investigated.</Para>
            </Section2>
            <Section2 ID="Sec16">
              <Heading>ONY-P1</Heading>
              <Para TextBreak="No">Another whole tumor-cell vaccine under clinical investigation is ONY-P1 (Onyvax Ltd., London, UK), which consists of three tumor cell lines (LNCaP, P4E6, and OnyCap-23) targeting prostate cancer TAAs. Initial studies showed that intraepidermal administration of this type of vaccine with a mycobacterial adjuvant is well tolerated and generates immune responses [<CitationRef CitationID="CR98_27">98</CitationRef>]. A later phase II study was done in 26 patients with CRPC without metastasis to the bone. The first two doses were administered biweekly with BCG as an adjuvant. Subsequently, the vaccine was given alone monthly for up to 12 months. Forty-two percent of patients had a statistically significant decline in PSA velocity, which correlated with an immune response [<CitationRef CitationID="CR99_27">99</CitationRef>]. A multicenter phase II placebo-controlled study with ONY-P1 has completed enrollment, and a second phase II study of ONY-P1 following limited ADT in castration-sensitive prostate cancer is ongoing at the NCI.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec17">
            <Heading>Future Directions</Heading>
            <Section2 ID="Sec18">
              <Heading>Regulatory T-Cell Depletion</Heading>
              <Para TextBreak="No">Tregs help to regulate the body’s immune response by maintaining a degree of self-tolerance and thereby decreasing autoimmunity [<CitationRef CitationID="CR100_27">100</CitationRef>–<CitationRef CitationID="CR102_27">102</CitationRef>]. Tregs, which make up 5–10% of circulating CD4<Superscript>+</Superscript> T cells, have the ability to suppress the activation and expansion of cytolytic T cells; thus, they can potentially limit the effectiveness of a vaccine designed to stimulate cytolytic T cells against TAAs [<CitationRef CitationID="CR103_27">103</CitationRef>, <CitationRef CitationID="CR104_27">104</CitationRef>]. Furthermore, animal studies have shown that the number and activity of Tregs within tumors and peripheral blood increase with tumor burden [<CitationRef CitationID="CR105_27">105</CitationRef>, <CitationRef CitationID="CR106_27">106</CitationRef>]. This has also been seen in human cancer patients, where higher levels of Tregs have also been correlated with poor outcome [<CitationRef CitationID="CR107_27">107</CitationRef>–<CitationRef CitationID="CR110_27">110</CitationRef>].</Para>
              <Para TextBreak="No">Experiments in preclinical models have demonstrated that selective removal of Tregs can enable a tumor-specific immune response [<CitationRef CitationID="CR106_27">106</CitationRef>, <CitationRef CitationID="CR111_27">111</CitationRef>, <CitationRef CitationID="CR112_27">112</CitationRef>]. Several methods of Treg depletion are under investigation [<CitationRef CitationID="CR113_27">113</CitationRef>]. Low doses of the chemotherapy agent cyclophosphamide have been shown to selectively decrease the number and function of Tregs while leaving cytolytic T cells unaffected [<CitationRef CitationID="CR43_27">43</CitationRef>, <CitationRef CitationID="CR114_27">114</CitationRef>]. In addition, Tregs have been shown to express CD25, a high-affinity IL-2 receptor. In recent years, several antibodies have been developed to selectively target this marker, with the goal of neutralizing Tregs [<CitationRef CitationID="CR109_27">109</CitationRef>, <CitationRef CitationID="CR115_27">115</CitationRef>–<CitationRef CitationID="CR117_27">117</CitationRef>]. As the understanding of the function of Tregs grows, new techniques may be developed to block their regulatory effects, thereby enhancing the effectiveness of vaccines in the treatment of cancer.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec19">
            <Heading>Evaluating Vaccines in the Clinical Setting</Heading>
            <Para TextBreak="No">Objective evaluation of disease response in metastatic CRPC is difficult. About 60% of patients have metastasis only to bone, which is best visualized by whole-body scintigraphy. Unfortunately, complete responses with whole-body scintigraphy are rare, and there are no widely accepted criteria for partial responses. Moreover, increasing radionuclide uptake is associated with bone healing (possibly a therapeutic response), trauma, and progressive disease, further complicating interpretation. Only about 40% of patients have measurable soft tissue disease (mainly lymph node metastasis). Thus, standard evaluation paradigms may not be appropriate for vaccine-based treatment modalities. Standard chemotherapeutic agents are evaluated based on the response evaluation criteria in solid tumors (RECIST), where clinical benefit is evaluated strictly by tumor size [<CitationRef CitationID="CR118_27">118</CitationRef>, <CitationRef CitationID="CR119_27">119</CitationRef>]. A review of the numerous trials of all three types of vaccines discussed here shows that clinical benefit as indicated by overall survival may be achieved in spite of early disease progression, which does not take into account a potentially burgeoning immune response [<CitationRef CitationID="CR82_27">82</CitationRef>, <CitationRef CitationID="CR90_27">90</CitationRef>, <CitationRef CitationID="CR96_27">96</CitationRef>] (Table <InternalRef RefID="Tab3">27.3</InternalRef>).<Table Float="Yes" ID="Tab3">
                <Caption Language="En">
                  <CaptionNumber>Table 27.3</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Vaccine trials showing improved survival in spite of lack of time to progression benefit</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="5">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <colspec colname="c3" colnum="3"/>
                  <colspec colname="c4" colnum="4"/>
                  <colspec colname="c5" colnum="5"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>References</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Vaccine</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>
                          <Emphasis Type="Italic">n</Emphasis>
                        </SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Patients</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Results</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>[<CitationRef CitationID="CR82_27">82</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>PSA-TRICOM</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>125</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>mCRPC GS ≤ 7</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Median OS was 24.4 mos for patients treated with vaccine compared to 16.3 mos for patients treated with an empty poxviral vector (randomized 2:1)</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>[<CitationRef CitationID="CR90_27">90</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Sipuleucel-T</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>127</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>mCRPC</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>TTP favored vaccine (16.6 vs. 10 wks; <Emphasis Type="Italic">p</Emphasis> = 0.052). Median OS favored vaccine 25.9 vs. 21.4 (<Emphasis Type="Italic">p</Emphasis> = 0.01). At 36 mos, estimated OS was 34.1% for vaccine and 11% for placebo (<Emphasis Type="Italic">p</Emphasis> = 0.005) (randomized 2:1)</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>[<CitationRef CitationID="CR96_27">96</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>GVAX</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>80</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>mCRPC</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Study randomized patients to increasing dose levels and a dose effect was seen. OS favored high doses (35 mos) compared to medium (20 mos) and low doses (23.1 mos)</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
                <tfooter>
                  <SimplePara>
                    <Emphasis Type="Italic">mCRPC</Emphasis> metastatic castration-resistant prostate cancer; <Emphasis Type="Italic">GS</Emphasis> Gleason score; <Emphasis Type="Italic">OS</Emphasis> overall survival; <Emphasis Type="Italic">TTP</Emphasis> time to progression; <Emphasis Type="Italic">mos</Emphasis> months; <Emphasis Type="Italic">wks</Emphasis> weeks</SimplePara>
                </tfooter>
              </Table>
            </Para>
            <Para TextBreak="No">One complicating factor in immunotherapy trials is that waxing/waning lymph nodes may represent vaccine-driven therapeutic changes that can be misconstrued as progressive disease [<CitationRef CitationID="CR120_27">120</CitationRef>–<CitationRef CitationID="CR122_27">122</CitationRef>]. Furthermore, despite initial disease progression as measured by RECIST, subsequent therapies may exploit a smoldering immune response. Alternatively, ensuing therapies may enhance the immune response by eliminating Tregs or by exposing an active immune response to new TAAs through either chemotherapy-mediated cell lysis or treatment-induced tumor phenotypic alterations. To determine one potential clinical utility of vaccines, future clinical trials may need to randomize patients to vaccine followed by standard therapy compared with standard therapy alone to determine the benefits of sequential therapy [<CitationRef CitationID="CR123_27">123</CitationRef>], and employ survival as the primary endpoint.</Para>
            <Para TextBreak="No">Based on results of the clinical trials reviewed here, it appears that certain patients derive greater clinical benefit from prostate cancer vaccines than do other patients, a significant consideration in issues such as FDA approval and the design of future clinical trials. An instructive example is trastuzumab, an agent targeted against Her-2-positive breast cancer that likely would not have gained FDA approval had it been tested in patients with all types of breast cancer. Similarly, identifying the characteristic(s) of the subpopulation that will derive the greatest benefit from prostate cancer vaccines – whether that is disease burden, an aspect of the immune system, or a combination of both – must be the focus of future clinical trials. What seems clear is that the patient population classically represented in clinical trials – those previously treated with multiple therapies or who have a large disease burden – is not the appropriate population for clinically evaluating the effectiveness of a vaccine [<CitationRef CitationID="CR124_27">124</CitationRef>]. That is why prostate cancer, an often indolent disease with a tumor marker (PSA) to detect low disease burden, may present a promising opportunity for defining the initial role of vaccines in cancer therapy.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_27.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_27">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Berry</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <IssueID>15</IssueID>
                <FirstPage>1502</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470213</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7s%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1056/NEJMoa040720</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_27">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <IssueID>15</IssueID>
                <FirstPage>1513</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470214</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7c%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1056/NEJMoa041318</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_27">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Sharifi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Androgen deprivation therapy for prostate cancer</ArticleTitle>
                <JournalTitle>JAMA</JournalTitle>
                <VolumeID>294</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>238</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>16014598</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXmtlSlt7g%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1001/jama.294.2.238</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294(2):238–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_27">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DS</Initials>
                  <FamilyName>Coffey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Isaacs</FamilyName>
                </BibAuthorName>
                <Year>1981</Year>
                <ArticleTitle Language="En">Prostate tumor biology and cell kinetics – theory</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>17</VolumeID>
                <IssueID>Suppl 3</IssueID>
                <FirstPage>40</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>7010755</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL3M7lsVOgsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Coffey DS, Isaacs JT. Prostate tumor biology and cell kinetics – theory. Urology 1981;17 Suppl 3:40–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_27">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Rhodes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TR</Initials>
                  <FamilyName>Barrette</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Rubin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Ghosh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Chinnaiyan</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>62</VolumeID>
                <IssueID>15</IssueID>
                <FirstPage>4427</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>12154050</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XlvFelu7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002;62(15):4427–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_27">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Fong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Immunotherapy for prostate cancer</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>30</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>649</FirstPage>
                <LastPage>58</LastPage>
                <Occurrence Type="PID">
                  <Handle>14571412</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXpt1Gksb8%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/S0093-7754(03)00350-6</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol 2003;30(5):649–58.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_27">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NG</Initials>
                  <FamilyName>Chakraborty</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Stevens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Mehrotra</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation</ArticleTitle>
                <JournalTitle>Cancer Immunol Immunother</JournalTitle>
                <VolumeID>52</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>497</FirstPage>
                <LastPage>505</LastPage>
                <Occurrence Type="PID">
                  <Handle>12783216</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXlsFKmsbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chakraborty NG, Stevens RL, Mehrotra S, et al. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother 2003;52(8):497–505.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_27">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Oesterling</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>145</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>907</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>1707989</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3M3gt1KlsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145(5):907–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_27">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Madan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">PSA-based vaccines for the treatment of prostate cancer</ArticleTitle>
                <JournalTitle>Expert Rev Vaccines</JournalTitle>
                <VolumeID>5</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>199</FirstPage>
                <LastPage>209</LastPage>
                <Occurrence Type="PID">
                  <Handle>16608420</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XktVGrtbg%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1586/14760584.5.2.199</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Madan RA, Gulley JL, Arlen PM. PSA-based vaccines for the treatment of prostate cancer. Expert Rev Vaccines 2006;5(2):199–209.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_27">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GP</Initials>
                  <FamilyName>Murphy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AA</Initials>
                  <FamilyName>Elgamal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Su</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>Bostwick</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EH</Initials>
                  <FamilyName>Holmes</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>83</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>2259</FirstPage>
                <LastPage>69</LastPage>
                <Occurrence Type="PID">
                  <Handle>9840525</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M%2FlsValsg%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/(SICI)1097-0142(19981201)83:11%3C2259::AID-CNCR5%3E3.3.CO;2-K</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998;83(11):2259–69.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_27">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GL</Initials>
                  <FamilyName>Wright</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BM</Initials>
                  <FamilyName>Grob</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Haley</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>48</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>326</FirstPage>
                <LastPage>34</LastPage>
                <Occurrence Type="PID">
                  <Handle>8753752</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/S0090-4295(96)00184-7</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Wright Jr GL, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48(2):326–34.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_27">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Veeramani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TC</Initials>
                  <FamilyName>Yuan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer</ArticleTitle>
                <JournalTitle>Endocr Relat Cancer</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>805</FirstPage>
                <LastPage>22</LastPage>
                <Occurrence Type="PID">
                  <Handle>16322323</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XnvVyjsA%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1677/erc.1.00950</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Veeramani S, Yuan TC, Chen SJ, et al. Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer 2005;12(4):805–22.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_27">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Vihko</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Virkkunen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Henttu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Roiko</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Solin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ML</Initials>
                  <FamilyName>Huhtala</FamilyName>
                </BibAuthorName>
                <Year>1988</Year>
                <ArticleTitle Language="En">Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase</ArticleTitle>
                <JournalTitle>FEBS Lett</JournalTitle>
                <VolumeID>236</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>275</FirstPage>
                <LastPage>81</LastPage>
                <Occurrence Type="PID">
                  <Handle>2842184</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXhs1Oju7o%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/0014-5793(88)80037-1</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Vihko P, Virkkunen P, Henttu P, Roiko K, Solin T, Huhtala ML. Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett 1988;236(2):275–81.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_27">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ML</Initials>
                  <FamilyName>Disis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Bernhard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FM</Initials>
                  <FamilyName>Shiota</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines</ArticleTitle>
                <JournalTitle>Blood</JournalTitle>
                <VolumeID>88</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>202</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>8704175</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XjvFSntro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Disis ML, Bernhard H, Shiota FM, et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996;88(1):202–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_27">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Dranoff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Jaffee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Lazenby</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>90</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>3539</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="PID">
                  <Handle>8097319</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXktVKqt78%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1073/pnas.90.8.3539</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90(8):3539–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_27">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Morrissey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Bressler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LS</Initials>
                  <FamilyName>Park</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Alpert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Gillis</FamilyName>
                </BibAuthorName>
                <Year>1987</Year>
                <ArticleTitle Language="En">Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>139</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>1113</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>3038997</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2sXlsleqtbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Morrissey PJ, Bressler L, Park LS, Alpert A, Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol 1987;139(4):1113–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_27">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Reese</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Um</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Whisenant</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SC</Initials>
                  <FamilyName>Dixon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>5</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>1738</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>10430077</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXltVCqtrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999;5(7):1738–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_27">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WM</Initials>
                  <FamilyName>Aarts</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Hodge</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>62</VolumeID>
                <IssueID>20</IssueID>
                <FirstPage>5770</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>12384537</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XotFyktro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002;62(20):5770–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_27">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Grosenbach</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Barrientos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Hodge</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>61</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>4497</FirstPage>
                <LastPage>505</LastPage>
                <Occurrence Type="PID">
                  <Handle>11389081</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXktlWjs7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001;61(11):4497–505.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_27">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Kass</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Panicali</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Mazzara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Greiner</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>61</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>206</FirstPage>
                <LastPage>14</LastPage>
                <Occurrence Type="PID">
                  <Handle>11196163</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXlsl2ktw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 2001;61(1):206–14.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_27">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Ward</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>McNeel</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer</ArticleTitle>
                <JournalTitle>Expert Opin Biol Ther</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>1893</FirstPage>
                <LastPage>902</LastPage>
                <Occurrence Type="PID">
                  <Handle>18034654</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtlClsLfM</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1517/14712598.7.12.1893</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Ward JE, McNeel DG. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther 2007;7(12):1893–902.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_27">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AG</Initials>
                  <FamilyName>Wingren</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Parra</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Varga</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles</ArticleTitle>
                <JournalTitle>Crit Rev Immunol</JournalTitle>
                <VolumeID>15</VolumeID>
                <IssueID>3–4</IssueID>
                <FirstPage>235</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>8834450</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28Xhs1ygsr8%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1615/CritRevImmunol.v15.i3-4.30</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Wingren AG, Parra E, Varga M, et al. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol 1995;15(3–4):235–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_27">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Madan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Enhancing efficacy of therapeutic vaccinations by combination with other modalities</ArticleTitle>
                <JournalTitle>Vaccine</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>Suppl 2</IssueID>
                <FirstPage>B89</FirstPage>
                <LastPage>96</LastPage>
                <Occurrence Type="PID">
                  <Handle>17573164</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtFequr3J</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/j.vaccine.2007.04.091</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 2007;25 Suppl 2:B89–96.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_27">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Aragon-Ching</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KM</Initials>
                  <FamilyName>Williams</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer</ArticleTitle>
                <JournalTitle>Front Biosci</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>4957</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>17569623</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXosF2qsrk%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.2741/2441</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007;12:4957–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_27">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Mercader</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BK</Initials>
                  <FamilyName>Bodner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MT</Initials>
                  <FamilyName>Moser</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>98</VolumeID>
                <IssueID>25</IssueID>
                <FirstPage>14565</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>11734652</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXptFCks7g%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1073/pnas.251140998</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001;98(25):14565–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_27">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Matejuk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Hopke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AA</Initials>
                  <FamilyName>Vandenbark</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PD</Initials>
                  <FamilyName>Hurn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Offner</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Middle-age male mice have increased severity of experimental autoimmune encephalomyelitis and are unresponsive to testosterone therapy</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>174</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>2387</FirstPage>
                <LastPage>95</LastPage>
                <Occurrence Type="PID">
                  <Handle>15699175</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtV2rtLo%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.4049/jimmunol.174.4.2387</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Matejuk A, Hopke C, Vandenbark AA, Hurn PD, Offner H. Middle-age male mice have increased severity of experimental autoimmune encephalomyelitis and are unresponsive to testosterone therapy. J Immunol 2005;174(4):2387–95.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_27">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GL</Initials>
                  <FamilyName>Goldberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Sutherland</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MV</Initials>
                  <FamilyName>Hammet</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Sex steroid ablation enhances lymphoid recovery following autologous hematopoietic stem cell transplantation</ArticleTitle>
                <JournalTitle>Transplantation</JournalTitle>
                <VolumeID>80</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>1604</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>16371932</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1097/01.tp.0000183962.64777.da</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Goldberg GL, Sutherland JS, Hammet MV, et al. Sex steroid ablation enhances lymphoid recovery following autologous hematopoietic stem cell transplantation. Transplantation 2005;80(11):1604–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_27">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CG</Initials>
                  <FamilyName>Drake</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AD</Initials>
                  <FamilyName>Doody</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Mihalyo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen</ArticleTitle>
                <JournalTitle>Cancer Cell</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>239</FirstPage>
                <LastPage>49</LastPage>
                <Occurrence Type="PID">
                  <Handle>15766662</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXivFCqu74%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/j.ccr.2005.01.027</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7(3):239–49.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_27">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Sutherland</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GL</Initials>
                  <FamilyName>Goldberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MV</Initials>
                  <FamilyName>Hammett</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Activation of thymic regeneration in mice and humans following androgen blockade</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>175</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>2741</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>16081852</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXntVSqsbY%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.4049/jimmunol.175.4.2741</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Sutherland JS, Goldberg GL, Hammett MV, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005;175(4):2741–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_27">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Prostate cancer update: 2007</ArticleTitle>
                <JournalTitle>Curr Opin Oncol</JournalTitle>
                <VolumeID>20</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>294</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>18391629</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1097/CCO.0b013e3282f8b075</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Lin AM, Small EJ. Prostate cancer update: 2007. Curr Opin Oncol 2008;20(3):294–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_27">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Chakraborty</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SI</Initials>
                  <FamilyName>Abrams</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Camphausen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>170</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>6338</FirstPage>
                <LastPage>47</LastPage>
                <Occurrence Type="PID">
                  <Handle>12794167</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXktlKrtbw%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.4049/jimmunol.170.12.6338</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170(12):6338–47.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_27">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CT</Initials>
                  <FamilyName>Garnett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Palena</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Chakraborty</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KY</Initials>
                  <FamilyName>Tsang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Hodge</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <IssueID>21</IssueID>
                <FirstPage>7985</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>15520206</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXptFels7s%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/0008-5472.CAN-04-1525</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64(21):7985–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_27">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Friedman</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Immune modulation by ionizing radiation and its implications for cancer immunotherapy</ArticleTitle>
                <JournalTitle>Curr Pharm Des</JournalTitle>
                <VolumeID>8</VolumeID>
                <IssueID>19</IssueID>
                <FirstPage>1765</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>12171547</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XlslKhtrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8(19):1765–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_27">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Bastian</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>3353</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>15867235</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjslOqtrc%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-04-2062</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11(9):3353–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_27">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EE</Initials>
                  <FamilyName>AbdAlla</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GE</Initials>
                  <FamilyName>Blair</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Jones</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HM</Initials>
                  <FamilyName>Sue-Ling</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Johnston</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>87</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>489</FirstPage>
                <LastPage>96</LastPage>
                <Occurrence Type="PID">
                  <Handle>7707435</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXlsVequrY%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1093/jnci/87.7.489</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>AbdAlla EE, Blair GE, Jones RA, Sue-Ling HM, Johnston D. Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. J Natl Cancer Inst 1995;87(7):489–96.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_27">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Fisk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CG</Initials>
                  <FamilyName>Ioannides</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Increased sensitivity of adriamycin-selected tumor lines to CTL-mediated lysis results in enhanced drug sensitivity</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>58</VolumeID>
                <IssueID>21</IssueID>
                <FirstPage>4790</FirstPage>
                <LastPage>3</LastPage>
                <Occurrence Type="PID">
                  <Handle>9809978</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXnt1yisr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fisk B, Ioannides CG. Increased sensitivity of adriamycin-selected tumor lines to CTL-mediated lysis results in enhanced drug sensitivity. Cancer Res 1998;58(21):4790–3.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_27">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Aquino</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Prete</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Greiner</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>4</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>2473</FirstPage>
                <LastPage>81</LastPage>
                <Occurrence Type="PID">
                  <Handle>9796980</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmvFykur4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Aquino A, Prete SP, Greiner JW, et al. Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. Clin Cancer Res 1998;4(10):2473–81.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_27">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Matsuzaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Suzuki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kitamura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Minamiya</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kawai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Ogawa</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells</ArticleTitle>
                <JournalTitle>Oncology</JournalTitle>
                <VolumeID>59</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>336</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="PID">
                  <Handle>11096347</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXovVersrg%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1159/000012192</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Matsuzaki I, Suzuki H, Kitamura M, Minamiya Y, Kawai H, Ogawa J. Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells. Oncology 2000;59(4):336–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_27">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CT</Initials>
                  <FamilyName>Garnett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Hodge</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>3536</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>18519787</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXmslygtrc%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-07-4025</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008;14(11):3536–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_27">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Orsini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Pavelic</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Mihich</FamilyName>
                </BibAuthorName>
                <Year>1977</Year>
                <ArticleTitle Language="En">Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>37</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1719</FirstPage>
                <LastPage>26</LastPage>
                <Occurrence Type="PID">
                  <Handle>66985</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE2sXltFWmsLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Orsini F, Pavelic Z, Mihich E. Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res 1977;37(6):1719–26.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_27">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Maccubbin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KR</Initials>
                  <FamilyName>Wing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KF</Initials>
                  <FamilyName>Mace</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Ho</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Ehrke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Mihich</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Adriamycin-induced modulation of host defenses in tumor-bearing mice</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>52</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>3572</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>1617626</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38XkvVejt7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Maccubbin DL, Wing KR, Mace KF, Ho RL, Ehrke MJ, Mihich E. Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res 1992;52(13):3572–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_27">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>OT</Initials>
                  <FamilyName>Chan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LX</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">The immunological effects of taxanes</ArticleTitle>
                <JournalTitle>Cancer Immunol Immunother</JournalTitle>
                <VolumeID>49</VolumeID>
                <IssueID>4–5</IssueID>
                <FirstPage>181</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>10941900</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXlvFymsb8%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1007/s002620000122</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother 2000;49(4–5):181–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_27">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Lutsiak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RT</Initials>
                  <FamilyName>Semnani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Pascalis</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SV</Initials>
                  <FamilyName>Kashmiri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Sabzevari</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide</ArticleTitle>
                <JournalTitle>Blood</JournalTitle>
                <VolumeID>105</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>2862</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>15591121</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXivFGmtLw%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1182/blood-2004-06-2410</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105(7):2862–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_27">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Ercolini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BH</Initials>
                  <FamilyName>Ladle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Manning</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response</ArticleTitle>
                <JournalTitle>J Exp Med</JournalTitle>
                <VolumeID>201</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>1591</FirstPage>
                <LastPage>602</LastPage>
                <Occurrence Type="PID">
                  <Handle>15883172</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXktlygu7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ercolini AM, Ladle BH, Manning EA, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005;201(10):1591–602.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_27">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Parker</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>1260</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16489082</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhsFaltb8%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-05-2059</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12(4):1260–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_27">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JG</Initials>
                  <FamilyName>Gribben</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Ryan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Boyajian</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>4430</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>15958627</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXltFeksrg%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-04-2111</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Gribben JG, Ryan DP, Boyajian R, et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005;11(12):4430–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_27">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Antonia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Mirza</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Fricke</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>3 Pt 1</IssueID>
                <FirstPage>878</FirstPage>
                <LastPage>87</LastPage>
                <Occurrence Type="PID">
                  <Handle>16467102</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFeiu7w%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-05-2013</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12(3 Pt 1):878–87.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_27">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Sacks</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Nemunaitis</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Granulocyte macrophage colony-stimulating factor – secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>3883</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="PID">
                  <Handle>17606721</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXntFymtrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor – secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007;13(13):3883–91.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_27">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Mueller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MK</Initials>
                  <FamilyName>Jenkins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RH</Initials>
                  <FamilyName>Schwartz</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy</ArticleTitle>
                <JournalTitle>Annu Rev Immunol</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>445</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>2653373</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL1M3ivVKntQ%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1146/annurev.iy.07.040189.002305</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989;7:445–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_27">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Waterhouse</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Penninger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Timms</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>270</VolumeID>
                <IssueID>5238</IssueID>
                <FirstPage>985</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>7481803</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXptlOlurk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995;270(5238):985–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_27">
              <CitationNumber>51</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Leach</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MF</Initials>
                  <FamilyName>Krummel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Allison</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Enhancement of antitumor immunity by CTLA-4 blockade</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>271</VolumeID>
                <IssueID>5256</IssueID>
                <FirstPage>1734</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>8596936</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XhvVWmsLk%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1126/science.271.5256.1734</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271(5256):1734–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_27">
              <CitationNumber>52</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Quezada</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KS</Initials>
                  <FamilyName>Peggs</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Curran</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Allison</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells</ArticleTitle>
                <JournalTitle>J Clin Invest</JournalTitle>
                <VolumeID>116</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>1935</FirstPage>
                <LastPage>45</LastPage>
                <Occurrence Type="PID">
                  <Handle>16778987</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XmvV2lurw%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1172/JCI27745</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116(7):1935–45.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_27">
              <CitationNumber>53</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HJ</Initials>
                  <FamilyName>Zeh</FamilyName>
                  <Suffix>III</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Perry-Lalley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Dudley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Rosenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>162</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>989</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>9916724</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXovFyjsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zeh III HJ, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162(2):989–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_27">
              <CitationNumber>54</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Hodge</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Chakraborty</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Kudo-Saito</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CT</Initials>
                  <FamilyName>Garnett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Multiple costimulatory modalities enhance CTL avidity</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>174</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>5994</FirstPage>
                <LastPage>6004</LastPage>
                <Occurrence Type="PID">
                  <Handle>15879092</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjvV2msbY%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.4049/jimmunol.174.10.5994</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J. Multiple costimulatory modalities enhance CTL avidity. J Immunol 2005;174(10):5994–6004.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_27">
              <CitationNumber>55</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JG</Initials>
                  <FamilyName>Egen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Kuhns</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Allison</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">CTLA-4: new insights into its biological function and use in tumor immunotherapy</ArticleTitle>
                <JournalTitle>Nat Immunol</JournalTitle>
                <VolumeID>3</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>611</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>12087419</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xksl2mtbs%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1038/ni0702-611</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3(7):611–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_27">
              <CitationNumber>56</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Allison</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Chambers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hurwitz</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance?</ArticleTitle>
                <JournalTitle>Novartis Found Symp</JournalTitle>
                <VolumeID>215</VolumeID>
                <FirstPage>92</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>9760573</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXpsFKl</Handle>
                </Occurrence>
                <BibComments>Discussion 8–102, 86–90</BibComments>
              </BibArticle>
              <BibUnstructured>Allison JP, Chambers C, Hurwitz A, et al. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Novartis Found Symp 1998;215:92–8. Discussion 8–102, 86–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_27">
              <CitationNumber>57</CitationNumber>
              <BibUnstructured>Gerritsen W, Van Den Eertwegh A, De Gruijl T, et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with fully human anti-CTL4 antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC) [abstract]. ASCO Prostate Cancer Symposium 2007:262.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_27">
              <CitationNumber>58</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Gerritsen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Van Den Eertwegh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>De Gruijl</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC) [abstract]</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>Suppl</IssueID>
                <FirstPage>5146</FirstPage>
              </BibArticle>
              <BibUnstructured>Gerritsen W, Van Den Eertwegh A, De Gruijl T. Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC) [abstract]. J Clin Oncol 2008;26(Suppl):5146.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_27">
              <CitationNumber>59</CitationNumber>
              <BibUnstructured>Gulley J, Arlen P, Madan R, et al. Phase I trial of a PSA based vaccine and ipilimumab in patients (pts) with metastatic castrate resistant prostate cancer (CRPC) [abstract]. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics Meeting Abstracts. October 2007:A142.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_27">
              <CitationNumber>60</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Essajee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>Kaufman</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Poxvirus vaccines for cancer and HIV therapy</ArticleTitle>
                <JournalTitle>Expert Opin Biol Ther</JournalTitle>
                <VolumeID>4</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>575</FirstPage>
                <LastPage>88</LastPage>
                <Occurrence Type="PID">
                  <Handle>15102606</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXis1OqtrY%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1517/14712598.4.4.575</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther 2004;4(4):575–88.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_27">
              <CitationNumber>61</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Kass</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Guadagni</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Graziano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Greiner</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>676</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>9973217</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXhtV2ru7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999;59(3):676–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_27">
              <CitationNumber>62</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Kantor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Abrams</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Irvine</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Snoy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kaufman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen</ArticleTitle>
                <JournalTitle>Ann N Y Acad Sci</JournalTitle>
                <VolumeID>690</VolumeID>
                <FirstPage>370</FirstPage>
                <LastPage>3</LastPage>
                <Occurrence Type="PID">
                  <Handle>8368759</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3sznvVensA%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1749-6632.1993.tb44034.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Kantor J, Abrams S, Irvine K, Snoy P, Kaufman H, Schlom J. Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen. Ann N Y Acad Sci 1993;690:370–3.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_27">
              <CitationNumber>63</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Hodge</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Grosenbach</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AN</Initials>
                  <FamilyName>Rad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Giuliano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Sabzevari</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules</ArticleTitle>
                <JournalTitle>Vaccine</JournalTitle>
                <VolumeID>19</VolumeID>
                <IssueID>25–26</IssueID>
                <FirstPage>3552</FirstPage>
                <LastPage>67</LastPage>
                <Occurrence Type="PID">
                  <Handle>11348723</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjtlCjsL0%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/S0264-410X(01)00062-7</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Hodge JW, Grosenbach DW, Rad AN, Giuliano M, Sabzevari H, Schlom J. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine 2001;19(25–26):3552–67.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_27">
              <CitationNumber>64</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Zhu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Terasawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>61</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>3725</FirstPage>
                <LastPage>34</LastPage>
                <Occurrence Type="PID">
                  <Handle>11325845</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjsFCgurg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhu M, Terasawa H, Gulley J, et al. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res 2001;61(9):3725–34.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_27">
              <CitationNumber>65</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Palena</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Zhu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KY</Initials>
                  <FamilyName>Tsang</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells</ArticleTitle>
                <JournalTitle>Blood</JournalTitle>
                <VolumeID>104</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>192</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15010371</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXlslWgsLg%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1182/blood-2003-09-3211</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Palena C, Zhu M, Schlom J, Tsang KY. Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells. Blood 2004;104(1):192–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_27">
              <CitationNumber>66</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Moss</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>93</VolumeID>
                <IssueID>21</IssueID>
                <FirstPage>11341</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>8876137</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28Xmtlagsrw%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1073/pnas.93.21.11341</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A 1996;93(21):11341–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_27">
              <CitationNumber>67</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AP</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>53</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>109</FirstPage>
                <LastPage>17</LastPage>
                <Occurrence Type="PID">
                  <Handle>12242725</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XosFSks7w%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/pros.10130</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Gulley J, Chen AP, Dahut W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002;53(2):109–17.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_27">
              <CitationNumber>68</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HM</Initials>
                  <FamilyName>Etlinger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Altenburger</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus</ArticleTitle>
                <JournalTitle>Vaccine</JournalTitle>
                <VolumeID>9</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>470</FirstPage>
                <LastPage>2</LastPage>
                <Occurrence Type="PID">
                  <Handle>1716807</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3Mznslaqtw%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/0264-410X(91)90030-A</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Etlinger HM, Altenburger W. Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus. Vaccine 1991;9(7):470–2.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_27">
              <CitationNumber>69</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Kundig</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CP</Initials>
                  <FamilyName>Kalberer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Hengartner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RM</Initials>
                  <FamilyName>Zinkernagel</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination</ArticleTitle>
                <JournalTitle>Vaccine</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>1154</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>8249436</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c%2FntVWhtQ%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/0264-410X(93)90079-D</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Kundig TM, Kalberer CP, Hengartner H, Zinkernagel RM. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 1993;11(11):1154–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_27">
              <CitationNumber>70</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Konishi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Pincus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Paoletti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Shope</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Wason</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens</ArticleTitle>
                <JournalTitle>Vaccine</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>633</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>8085382</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2czmslKhtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Konishi E, Pincus S, Paoletti E, Shope RE, Wason PW. Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens. Vaccine 1994;12(7):633–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_27">
              <CitationNumber>71</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Hodge</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>McLaughlin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Kantor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses</ArticleTitle>
                <JournalTitle>Vaccine</JournalTitle>
                <VolumeID>15</VolumeID>
                <IssueID>6–7</IssueID>
                <FirstPage>759</FirstPage>
                <LastPage>68</LastPage>
                <Occurrence Type="PID">
                  <Handle>9178479</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXktFGqu7o%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/S0264-410X(96)00238-1</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997;15(6–7):759–68.</BibUnstructured>
            </Citation>
            <Citation ID="CR72_27">
              <CitationNumber>72</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Marshall</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Hoyer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Toomey</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>23</IssueID>
                <FirstPage>3964</FirstPage>
                <LastPage>73</LastPage>
                <Occurrence Type="PID">
                  <Handle>11099326</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3M%2Fnt1GisQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18(23):3964–73.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_27">
              <CitationNumber>73</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>Kaufman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Manola</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>2122</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>15169798</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVWlsbw%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1200/JCO.2004.08.083</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22(11):2122–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_27">
              <CitationNumber>74</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kaufman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Manola</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>DiPaola</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Phase II prime/boost vaccination using poxviruses expressing PSA in hormone-dependent prostate cancer: follow-up clinical results from ECOG 7897 [abstract]</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <IssueID>16S</IssueID>
                <FirstPage>4501</FirstPage>
              </BibArticle>
              <BibUnstructured>Kaufman H, Wang W, Manola J, DiPaola R. Phase II prime/boost vaccination using poxviruses expressing PSA in hormone-dependent prostate cancer: follow-up clinical results from ECOG 7897 [abstract]. J Clin Oncol 2005;23(16S):4501.</BibUnstructured>
            </Citation>
            <Citation ID="CR75_27">
              <CitationNumber>75</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Lechleider</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KY</Initials>
                  <FamilyName>Tsang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin-2 is used as an adjuvant</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>16</IssueID>
                <FirstPage>5284</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="PID">
                  <Handle>18698048</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXpslKns7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lechleider RJ, Arlen PM, Tsang KY, et al. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin-2 is used as an adjuvant. Clin Cancer Res 2008;14(16):5284–91.</BibUnstructured>
            </Citation>
            <Citation ID="CR76_27">
              <CitationNumber>76</CitationNumber>
              <BibUnstructured>Clinical Trials (PDQ). Samarium Sm 153 lexidronam pentasodium with or without vaccine therapy and GM-CSF in treating patients with prostate cancer and bone metastases. Available from:<ExternalRef>
                  <RefSource>http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=535561&amp;version=patient&amp;protocolsearchid=4937826</RefSource>
                  <RefTarget Address="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=535561&amp;version=patient&amp;protocolsearchid=4937826" TargetType="URL"/>
                </ExternalRef>. Accessed Jul 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR77_27">
              <CitationNumber>77</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Todd</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>174</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>539</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>16006888</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXmtVWrtL0%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1097/01.ju.0000165159.33772.5b</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Arlen PM, Gulley JL, Todd N, et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005;174(2):539–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_27">
              <CitationNumber>78</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Madan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>14</IssueID>
                <FirstPage>4526</FirstPage>
                <LastPage>31</LastPage>
                <Occurrence Type="PID">
                  <Handle>18628467</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXosFGitLg%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-07-5048</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Madan RA, Gulley JL, Schlom J, et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 2008;14(14):4526–31.</BibUnstructured>
            </Citation>
            <Citation ID="CR79_27">
              <CitationNumber>79</CitationNumber>
              <BibUnstructured>Clinical Trials (PDQ). Flutamide with or without vaccine therapy in treating patients with nonmetastatic prostate cancer. Available from:<ExternalRef>
                  <RefSource>http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=535593&amp;version=patient&amp;protocolsearchid=4937826</RefSource>
                  <RefTarget Address="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=535593&amp;version=patient&amp;protocolsearchid=4937826" TargetType="URL"/>
                </ExternalRef>. Accessed Jul 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR80_27">
              <CitationNumber>80</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Hodge</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Sabzevari</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AG</Initials>
                  <FamilyName>Yafal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Gritz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Lorenz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">A triad of costimulatory molecules synergize to amplify T-cell activation</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <IssueID>22</IssueID>
                <FirstPage>5800</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10582702</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXnslyhu7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59(22):5800–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR81_27">
              <CitationNumber>81</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Skarupa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Pazdur</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Clinical safety of a viral vector based prostate cancer vaccine strategy</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>178</VolumeID>
                <IssueID>4 Pt 1</IssueID>
                <FirstPage>1515</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>17707059</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtFKnsbvK</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/j.juro.2007.05.117</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Arlen PM, Skarupa L, Pazdur M, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007;178(4 Pt 1):1515–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR82_27">
              <CitationNumber>82</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Glode</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Tannenbaum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Bilhartz</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients with hormone-refractory prostate cancer [abstract]</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <IssueID>18S</IssueID>
                <FirstPage>1501</FirstPage>
              </BibArticle>
              <BibUnstructured>Kantoff P, Glode L, Tannenbaum S, Bilhartz D. Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients with hormone-refractory prostate cancer [abstract]. J Clin Oncol 2005;24(18S):1501.</BibUnstructured>
            </Citation>
            <Citation ID="CR83_27">
              <CitationNumber>83</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Madan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): implications for clinical trial design [abstract]</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>16</VolumeID>
                <IssueID>20S</IssueID>
                <FirstPage>3005</FirstPage>
              </BibArticle>
              <BibUnstructured>Madan R, Gulley J, Dahut W, et al. Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): implications for clinical trial design [abstract]. J Clin Oncol 2008;16(20S):3005.</BibUnstructured>
            </Citation>
            <Citation ID="CR84_27">
              <CitationNumber>84</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>21</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>1232</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>12663709</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1200/JCO.2003.06.100</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21(7):1232–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR85_27">
              <CitationNumber>85</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BI</Initials>
                  <FamilyName>Rini</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Technology evaluation: APC-8015, Dendreon</ArticleTitle>
                <JournalTitle>Curr Opin Mol Ther</JournalTitle>
                <VolumeID>4</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>76</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11883698</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XlvVKrtr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rini BI. Technology evaluation: APC-8015, Dendreon. Curr Opin Mol Ther 2002;4(1):76–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR86_27">
              <CitationNumber>86</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PH</Initials>
                  <FamilyName>Patel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Kockler</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Ann Pharmacother</JournalTitle>
                <VolumeID>42</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>91</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>18094343</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1345/aph.1K429</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Patel PH, Kockler DR. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother 2008;42(1):91–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR87_27">
              <CitationNumber>87</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Burch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Breen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Buckner</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>6</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>2175</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>10873066</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXksVGhsr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000;6(6):2175–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR88_27">
              <CitationNumber>88</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Fratesi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Reese</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>23</IssueID>
                <FirstPage>3894</FirstPage>
                <LastPage>903</LastPage>
                <Occurrence Type="PID">
                  <Handle>11099318</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXptVSiurc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18(23):3894–903.</BibUnstructured>
            </Citation>
            <Citation ID="CR89_27">
              <CitationNumber>89</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Burch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Croghan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Gastineau</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>60</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>197</FirstPage>
                <LastPage>204</LastPage>
                <Occurrence Type="PID">
                  <Handle>15176049</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXntFGks78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate 2004;60(3):197–204.</BibUnstructured>
            </Citation>
            <Citation ID="CR90_27">
              <CitationNumber>90</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PF</Initials>
                  <FamilyName>Schellhammer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Higano</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <IssueID>19</IssueID>
                <FirstPage>3089</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>16809734</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XnslKhs7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19):3089–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR91_27">
              <CitationNumber>91</CitationNumber>
              <BibUnstructured>US Food and Drug Administration, Cellular, Tissue and Gene Therapies Advisory Committee. Sipuleucel-T briefing document. Dendreon Corporation. Available from:<ExternalRef>
                  <RefSource>http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4291B1_01.pdf</RefSource>
                  <RefTarget Address="http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4291B1_01.pdf" TargetType="URL"/>
                </ExternalRef>. Accessed Jul 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR92_27">
              <CitationNumber>92</CitationNumber>
              <BibUnstructured>Dendreon expects interim data analysis for phase 3 PROVENGE IMPACT Trial in October. Available from:<ExternalRef>
                  <RefSource>http://www.investor.dendreon.com/newsroom/releasedetail.cfm?ReleaseID=323910&amp;header=News</RefSource>
                  <RefTarget Address="http://www.investor.dendreon.com/newsroom/releasedetail.cfm?ReleaseID=323910&amp;header=News" TargetType="URL"/>
                </ExternalRef>. Accessed Aug 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR93_27">
              <CitationNumber>93</CitationNumber>
              <BibUnstructured>Clinical Trials (PDQ). Sipuleucel-T as neoadjuvant treatment in prostate cancer. Available from:<ExternalRef>
                  <RefSource>http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=601177&amp;version=HealthProfessional&amp;protocolsearchid=5006778</RefSource>
                  <RefTarget Address="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=601177&amp;version=HealthProfessional&amp;protocolsearchid=5006778" TargetType="URL"/>
                </ExternalRef>. Accessed Aug 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR94_27">
              <CitationNumber>94</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Simons</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Mikhak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JF</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <IssueID>20</IssueID>
                <FirstPage>5160</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10537292</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXmvFels7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59(20):5160–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR95_27">
              <CitationNumber>95</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Simons</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Mikhak</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>11 Pt 1</IssueID>
                <FirstPage>3394</FirstPage>
                <LastPage>401</LastPage>
                <Occurrence Type="PID">
                  <Handle>16740763</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XltFyis7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Simons JW, Carducci MA, Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 2006;12(11 Pt 1):3394–401.</BibUnstructured>
            </Citation>
            <Citation ID="CR96_27">
              <CitationNumber>96</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Higano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Corman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DC</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>113</VolumeID>
                <FirstPage>975</FirstPage>
                <LastPage>84</LastPage>
                <Occurrence Type="PID">
                  <Handle>18646045</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtFSlur3F</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/cncr.23669</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008;113:975–84.</BibUnstructured>
            </Citation>
            <Citation ID="CR97_27">
              <CitationNumber>97</CitationNumber>
              <BibUnstructured>Cell Genesys, Inc. GVAX immunotherapy for prostate cancer. Available from:<ExternalRef>
                  <RefSource>http://www.cellgenesys.com/clinical-prostate-cancer.shtml</RefSource>
                  <RefTarget Address="http://www.cellgenesys.com/clinical-prostate-cancer.shtml" TargetType="URL"/>
                </ExternalRef>. Accessed Aug 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR98_27">
              <CitationNumber>98</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Eaton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Perry</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Nicholson</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>89</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>19</FirstPage>
                <LastPage>26</LastPage>
                <Occurrence Type="PID">
                  <Handle>11849155</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD387hsVOqtA%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1046/j.1464-410X.2002.02572.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Eaton JD, Perry MJ, Nicholson S, et al. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 2002;89(1):19–26.</BibUnstructured>
            </Citation>
            <Citation ID="CR99_27">
              <CitationNumber>99</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Michael</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Ball</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Quatan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>4469</FirstPage>
                <LastPage>78</LastPage>
                <Occurrence Type="PID">
                  <Handle>15958632</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXltFeks78%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-04-2337</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Michael A, Ball G, Quatan N, et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005;11(12):4469–78.</BibUnstructured>
            </Citation>
            <Citation ID="CR100_27">
              <CitationNumber>100</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Sakaguchi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Sakaguchi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Asano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Itoh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Toda</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>155</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>1151</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>7636184</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXntFWnurs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155(3):1151–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR101_27">
              <CitationNumber>101</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Morse</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Clay</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Mosca</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HK</Initials>
                  <FamilyName>Lyerly</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Immunoregulatory T cells in cancer immunotherapy</ArticleTitle>
                <JournalTitle>Expert Opin Biol Ther</JournalTitle>
                <VolumeID>2</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>827</FirstPage>
                <LastPage>34</LastPage>
                <Occurrence Type="PID">
                  <Handle>12517262</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXovFCk</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1517/14712598.2.8.827</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Morse MA, Clay TM, Mosca P, Lyerly HK. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther 2002;2(8):827–34.</BibUnstructured>
            </Citation>
            <Citation ID="CR102_27">
              <CitationNumber>102</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Sakaguchi</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Regulatory T cells: key controllers of immunologic self-tolerance</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>101</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>455</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10850488</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXjvFWntL4%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/S0092-8674(00)80856-9</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101(5):455–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR103_27">
              <CitationNumber>103</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Piccirillo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Shevach</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>167</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>1137</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>11466326</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXls1WktL0%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.4049/jimmunol.167.3.1137</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167(3):1137–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR104_27">
              <CitationNumber>104</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EY</Initials>
                  <FamilyName>Woo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Yeh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Chu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>168</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>4272</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>11970966</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xjt12jsLo%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.4049/jimmunol.168.9.4272</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168(9):4272–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR105_27">
              <CitationNumber>105</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Fu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Shen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Fujimoto</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Tumor-specific CD4(+) suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J mice</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>87</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>680</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10925362</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXlvFahur8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fu T, Shen Y, Fujimoto S. Tumor-specific CD4(+) suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J mice. Int J Cancer 2000;87(5):680–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR106_27">
              <CitationNumber>106</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Ghiringhelli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Larmonier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Schmitt</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative</ArticleTitle>
                <JournalTitle>Eur J Immunol</JournalTitle>
                <VolumeID>34</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>336</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>14768038</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhsFals7k%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/eji.200324181</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34(2):336–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR107_27">
              <CitationNumber>107</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Curiel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Coukos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Zou</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>942</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15322536</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXntFSkt7g%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1038/nm1093</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR108_27">
              <CitationNumber>108</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Sato</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SH</Initials>
                  <FamilyName>Olson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Ahn</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>102</VolumeID>
                <IssueID>51</IssueID>
                <FirstPage>18538</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="PID">
                  <Handle>16344461</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xpt1Om</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1073/pnas.0509182102</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102(51):18538–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR109_27">
              <CitationNumber>109</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kawaida</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Kono</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Takahashi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Distribution of CD4+CD25 high regulatory T cells in tumor-draining lymph nodes in patients with gastric cancer</ArticleTitle>
                <JournalTitle>J Surg Res</JournalTitle>
                <VolumeID>124</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>151</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>15734494</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhslWrsbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kawaida H, Kono K, Takahashi A, et al. Distribution of CD4+CD25 high regulatory T cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res 2005;124(1):151–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR110_27">
              <CitationNumber>110</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EY</Initials>
                  <FamilyName>Woo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Chu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Goletz</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>61</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>4766</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="PID">
                  <Handle>11406550</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXks1GrtbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61(12):4766–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR111_27">
              <CitationNumber>111</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Tanaka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Tanaka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Kjaergaard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Shu</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes</ArticleTitle>
                <JournalTitle>J Immunother</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>207</FirstPage>
                <LastPage>17</LastPage>
                <Occurrence Type="PID">
                  <Handle>12000862</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XksFWrur4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tanaka H, Tanaka J, Kjaergaard J, Shu S. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 2002;25(3):207–17.</BibUnstructured>
            </Citation>
            <Citation ID="CR112_27">
              <CitationNumber>112</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Jones</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Dahm-Vicker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AK</Initials>
                  <FamilyName>Simon</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice</ArticleTitle>
                <JournalTitle>Cancer Immun</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>1</FirstPage>
                <Occurrence Type="PID">
                  <Handle>12747746</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jones E, Dahm-Vicker M, Simon AK, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002;2:1.</BibUnstructured>
            </Citation>
            <Citation ID="CR113_27">
              <CitationNumber>113</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RH</Initials>
                  <FamilyName>Schabowsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Madireddi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Sharma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ES</Initials>
                  <FamilyName>Yolcu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Shirwan</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Targeting CD4+CD25+FoxP3+ regulatory T cells for the augmentation of cancer immunotherapy</ArticleTitle>
                <JournalTitle>Curr Opin Investig Drugs</JournalTitle>
                <VolumeID>8</VolumeID>
                <IssueID>12</IssueID>
                <FirstPage>1002</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>18058571</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXpslGktw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H. Targeting CD4+CD25+FoxP3+ regulatory T cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs 2007;8(12):1002–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR114_27">
              <CitationNumber>114</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Motoyoshi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Kaminoda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Saitoh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide</ArticleTitle>
                <JournalTitle>Oncol Rep</JournalTitle>
                <VolumeID>16</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>141</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>16786137</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xntlans70%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.3892/or.16.1.141</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Motoyoshi Y, Kaminoda K, Saitoh O, et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep 2006;16(1):141–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR115_27">
              <CitationNumber>115</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Strassburg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ED</Initials>
                  <FamilyName>Pfister</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Arning</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Nashan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JH</Initials>
                  <FamilyName>Ehrich</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Melter</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Basiliximab reduces acute liver allograft rejection in pediatric patients</ArticleTitle>
                <JournalTitle>Transplant Proc</JournalTitle>
                <VolumeID>34</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>2374</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>12270443</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xnt1Ggsbo%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/S0041-1345(02)03276-1</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Strassburg A, Pfister ED, Arning A, Nashan B, Ehrich JH, Melter M. Basiliximab reduces acute liver allograft rejection in pediatric patients. Transplant Proc 2002;34(6):2374–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR116_27">
              <CitationNumber>116</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GC</Initials>
                  <FamilyName>Furtado</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Curotto</FamilyName>
                  <Particle>de Lafaille</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Kutchukhidze</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Lafaille</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Interleukin 2 signaling is required for CD4(+) regulatory T cell function</ArticleTitle>
                <JournalTitle>J Exp Med</JournalTitle>
                <VolumeID>196</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>851</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>12235217</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xnt1yhtLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Furtado GC, de Lafaille Curotto MA, Kutchukhidze N, Lafaille JJ. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 2002;196(6):851–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR117_27">
              <CitationNumber>117</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Neuhaus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Clavien</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Kittur</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial</ArticleTitle>
                <JournalTitle>Liver Transpl</JournalTitle>
                <VolumeID>8</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>132</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>11862589</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1053/jlts.2002.30302</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002;8(2):132–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR118_27">
              <CitationNumber>118</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Therasse</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SG</Initials>
                  <FamilyName>Arbuck</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Eisenhauer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>92</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>205</FirstPage>
                <LastPage>16</LastPage>
                <Occurrence Type="PID">
                  <Handle>10655437</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3c7it1Gitg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205–16.</BibUnstructured>
            </Citation>
            <Citation ID="CR119_27">
              <CitationNumber>119</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Therasse</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Eisenhauer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Verweij</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">RECIST revisited: a review of validation studies on tumour assessment</ArticleTitle>
                <JournalTitle>Eur J Cancer</JournalTitle>
                <VolumeID>42</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>1031</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16616487</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD283nt1antQ%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1016/j.ejca.2006.01.026</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42(8):1031–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR120_27">
              <CitationNumber>120</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KY</Initials>
                  <FamilyName>Tsang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>3060</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>18483372</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXmtVCmtbo%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-08-0126</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008;14(10):3060–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR121_27">
              <CitationNumber>121</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Jones</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Cunningham</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Cook</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Ell</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes</ArticleTitle>
                <JournalTitle>Br J Radiol</JournalTitle>
                <VolumeID>77</VolumeID>
                <IssueID>913</IssueID>
                <FirstPage>74</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>14988145</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD2c%2FpslCqtA%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1259/bjr/19323466</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Jones RL, Cunningham D, Cook G, Ell PJ. Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes. Br J Radiol 2004;77(913):74–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR122_27">
              <CitationNumber>122</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BE</Initials>
                  <FamilyName>Loveland</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Zhao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>White</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>3 Pt 1</IssueID>
                <FirstPage>869</FirstPage>
                <LastPage>77</LastPage>
                <Occurrence Type="PID">
                  <Handle>16467101</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFeiu78%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-05-1574</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Loveland BE, Zhao A, White S, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006;12(3 Pt 1):869–77.</BibUnstructured>
            </Citation>
            <Citation ID="CR123_27">
              <CitationNumber>123</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schlom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Cancer vaccines: moving beyond current paradigms</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>3776</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>17606707</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXntFymsbw%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1158/1078-0432.CCR-07-0588</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007;13(13):3776–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR124_27">
              <CitationNumber>124</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Mehren</FamilyName>
                  <Particle>von</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Arlen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1181</FirstPage>
                <LastPage>91</LastPage>
              </BibArticle>
              <BibUnstructured>von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7(5):1181–91.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
